ATE247953T1 - Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure - Google Patents

Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure

Info

Publication number
ATE247953T1
ATE247953T1 AT00910786T AT00910786T ATE247953T1 AT E247953 T1 ATE247953 T1 AT E247953T1 AT 00910786 T AT00910786 T AT 00910786T AT 00910786 T AT00910786 T AT 00910786T AT E247953 T1 ATE247953 T1 AT E247953T1
Authority
AT
Austria
Prior art keywords
isoquercetin
ascorbic acid
delayed
products containing
medicinal products
Prior art date
Application number
AT00910786T
Other languages
German (de)
English (en)
Inventor
Herwig Buchholz
Jerzy D Meduski
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE247953T1 publication Critical patent/ATE247953T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AT00910786T 1999-03-16 2000-03-08 Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure ATE247953T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12486399P 1999-03-16 1999-03-16
PCT/EP2000/002008 WO2000054754A2 (fr) 1999-03-16 2000-03-08 Composition comprenant de l'isoquercetine et de l'acide ascorbique a liberation prolongee

Publications (1)

Publication Number Publication Date
ATE247953T1 true ATE247953T1 (de) 2003-09-15

Family

ID=22417166

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00910786T ATE247953T1 (de) 1999-03-16 2000-03-08 Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure

Country Status (10)

Country Link
US (1) US6491948B1 (fr)
EP (1) EP1161228B1 (fr)
JP (1) JP2003526619A (fr)
AT (1) ATE247953T1 (fr)
AU (1) AU3287200A (fr)
CA (1) CA2367387C (fr)
DE (1) DE60004797T2 (fr)
DK (1) DK1161228T3 (fr)
ES (1) ES2204531T3 (fr)
WO (1) WO2000054754A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19809304A1 (de) * 1998-03-05 1999-09-09 Merck Patent Gmbh Formulierungen mit antiviraler Wirkung
WO2002043666A2 (fr) * 2000-10-31 2002-06-06 Colgate-Palmolive Company Composition et methode
DK1521572T3 (da) * 2002-07-15 2009-05-04 Alcon Inc Biologisk nedbrydelig film til indförsel af öjenlægemiddel
US20070087977A1 (en) * 2004-11-16 2007-04-19 Wendye Robbins Methods and compositions for treating pain
EP1817023A4 (fr) * 2004-11-16 2010-08-18 Limerick Biopharma Inc Procedes et compositions de traitement de douleurs
JP2006160668A (ja) * 2004-12-08 2006-06-22 Sanei Gen Ffi Inc 過酸化脂質生成抑制剤
US7745487B2 (en) * 2006-07-17 2010-06-29 Quercegen Pharma Llc Method for enhancing physical performance or immune system recovery from intense physical excercise with quercetin-containing compositions
US7745486B2 (en) * 2006-07-17 2010-06-29 Quercegen Pharma Llc Quercetin-containing compositions
EP2200605A4 (fr) * 2007-10-01 2011-03-23 Quercegen Pharma Llc Procédé de stabilisation de la quercétine
US8044096B2 (en) * 2008-01-18 2011-10-25 Quercegen Pharmaceuticals Llc Method for treating addiction using quercetin-containing compositions
US8574619B2 (en) * 2008-09-05 2013-11-05 Quercegen Pharmaceuticals, LLC Reducing cholesterol levels with combined use of quercetin and statin
US8034363B2 (en) * 2008-12-11 2011-10-11 Advanced Technologies And Regenerative Medicine, Llc. Sustained release systems of ascorbic acid phosphate
US9517249B2 (en) 2012-11-26 2016-12-13 Access Business Group International Llc Antioxidant dietary supplement and related method
JP6175048B2 (ja) * 2013-12-27 2017-08-02 花王株式会社 容器詰飲料
PL3042648T3 (pl) 2014-12-23 2019-12-31 Hermes Arzneimittel Gmbh Granulat do podawania bezpośredniego o opóźnionym uwalnianiu substancji czynnej
WO2017096049A1 (fr) 2015-12-03 2017-06-08 The University Of North Carolina At Pembroke Substances pour l'amélioration de la cathépsine b et méthodes d'utilisation
TWI761672B (zh) 2018-04-23 2022-04-21 日商阿爾卑斯藥品工業股份有限公司 O-醣苷基類黃酮之組成物
CA3121235A1 (fr) 2018-11-30 2020-06-04 Beth Israel Deaconess Medical Center, Inc. Compositions et methodes pour reduire les evenements thrombotiques majeurs chez les patients cancereux
US10617705B1 (en) * 2019-01-24 2020-04-14 Alps Pharmaceutical Ind. Co., Ltd. Isoquercitrin compositions
US10918654B1 (en) 2019-09-23 2021-02-16 Alps Pharmaceutical Ind. Co., Ltd. Rutin compositions
US11110109B2 (en) 2019-10-22 2021-09-07 Alps Pharmaceutical Ind. Co., Ltd. Water soluble O-glycosyl flavonoid compositions and methods for preparing same
CN113712982B (zh) * 2021-09-13 2022-12-06 广东金骏康生物技术有限公司 一种预防或治疗非酒精性脂肪肝、肥胖症的组合物及制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5944327A (ja) * 1982-09-06 1984-03-12 Taiyo Kagaku Kk L−アスコルビン酸およびその塩類の安定化法
JP2514201B2 (ja) * 1987-04-16 1996-07-10 横浜油脂工業株式会社 微粉状l−アスコルビン酸被覆物の製造方法
JPH01296953A (ja) * 1988-05-24 1989-11-30 Freunt Ind Co Ltd ビタミンc組成物、それを添加した飼料およびその製造方法
JP3016835B2 (ja) * 1990-08-19 2000-03-06 三栄源エフ・エフ・アイ株式会社 アスコルビン酸の褐変防止方法
JP2997303B2 (ja) * 1990-08-19 2000-01-11 三栄源エフ・エフ・アイ株式会社 褐変防止剤
JPH06199690A (ja) * 1992-03-06 1994-07-19 Yunie:Kk 脳代謝促進・脳機能改善剤
JPH06199693A (ja) * 1992-03-06 1994-07-19 Yunie:Kk 虚血性疾患改善治療剤
JPH0745402B2 (ja) * 1993-03-23 1995-05-17 信和薬品株式会社 持続性アスコルビン酸製剤
JPH07196523A (ja) * 1994-01-07 1995-08-01 Oomiya Yakugyo Kk ケルセチン配糖体を含有する内用液剤
US5972995A (en) * 1997-10-16 1999-10-26 Children's Hospital Medical Center Of Northern California Compositions and methods for cystic fibrosis therapy
US5972985A (en) * 1997-11-03 1999-10-26 Cytos Pharmaceuticals, Llc Histidine containing nutriceutical compositions

Also Published As

Publication number Publication date
CA2367387C (fr) 2009-06-23
US6491948B1 (en) 2002-12-10
AU3287200A (en) 2000-10-04
EP1161228A2 (fr) 2001-12-12
DE60004797D1 (de) 2003-10-02
CA2367387A1 (fr) 2000-09-21
DE60004797T2 (de) 2004-06-17
WO2000054754A2 (fr) 2000-09-21
WO2000054754A3 (fr) 2000-12-28
JP2003526619A (ja) 2003-09-09
ES2204531T3 (es) 2004-05-01
DK1161228T3 (da) 2003-11-24
EP1161228B1 (fr) 2003-08-27

Similar Documents

Publication Publication Date Title
ATE247953T1 (de) Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure
EP1283054A4 (fr) Medicaments permettant de traiter les complications du diabete et des neuropathies et utilisation de ces medicaments
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
TR200500745T2 (tr) Damar gelişimi inhibitörleri olarak kuinazolin türevleri.
ATE507246T1 (de) Wasserlösliche eisen-kohlenhydrat-komplexe, deren herstellung und diese enthaltende arzneimittel
HUP0203451A2 (hu) Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
DE602004022761D1 (de) Vitamine B3 und Vitamine C enthaltende Peelingzusammensetzung
ATE233752T1 (de) Liponsaürederivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
DK1289517T3 (da) Farmaceutiske sammensætninger indeholdende cannabidiolderivater
BR0211228A (pt) Composto, composição farmacêutica e seus usos
TW200630123A (en) Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
WO2005000232A3 (fr) Derives amino-amide a six elements tenant lieu d'inhibiteurs de l'angiogenese
CA2282082A1 (fr) Microgranules contenant du cisplatine
DE69923336D1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
ATE100323T1 (de) Verbesserungen betreffend die verabreichung pharmazeutischer mittel.
TNSN07203A1 (en) Pharmaceutical compositions for the treatment of cellulite
ATE286894T1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
HUP0600084A2 (en) Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient
SE0001916D0 (sv) Novel formulation
MY133230A (en) Combination of no synthase inhibitor(s) and metabolic antioxidant(s)
ATE286893T1 (de) 2h-1-benzopyran-derivative, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
HK1050203A1 (en) Novel fusidic acid derivatives.
EP2266566A3 (fr) Dérivés de nicotinamide et utilisation de ceux-ci comme agents thérapeutiques
EP1232748A4 (fr) Produit derive de type nitrobenzene substitue trouvant une application comme medicament ou autres produits efficaces

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties